These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19224851)

  • 1. Bendamustine: rebirth of an old drug.
    Cheson BD; Rummel MJ
    J Clin Oncol; 2009 Mar; 27(9):1492-501. PubMed ID: 19224851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ; Gregory SA
    Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine in the treatment of chronic lymphocytic leukemia.
    Knauf W
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine: something old, something new.
    Tageja N; Nagi J
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):413-23. PubMed ID: 20376452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine: a novel cytotoxic agent for hematologic malignancies.
    Blumel S; Goodrich A; Martin C; Dang NH
    Clin J Oncol Nurs; 2008 Oct; 12(5):799-806. PubMed ID: 18842536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine: a new look at an old drug.
    Kalaycio M
    Cancer; 2009 Feb; 115(3):473-9. PubMed ID: 19117340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century.
    Leoni LM
    Semin Hematol; 2011 Apr; 48 Suppl 1():S4-11. PubMed ID: 21530771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
    Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
    J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine therapy in chronic lymphocytic leukemia.
    Masiello D; Tulpule A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
    Ujjani C; Cheson B
    Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies.
    Korycka-WoĊ‚owiec A; Robak T
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1455-68. PubMed ID: 22970741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
    Chow KU; Boehrer S; Geduldig K; Krapohl A; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2001 May; 86(5):485-93. PubMed ID: 11410411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Elefante A; Czuczman MS
    Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine: new perspective for an old drug in lymphoproliferative disorders.
    Montillo M; Ricci F; Tedeschi A; Vismara E; Morra E
    Expert Rev Hematol; 2010 Apr; 3(2):131-48. PubMed ID: 21083456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
    Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
    J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
    Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.